First Study of its Kind
combining proven CBD with empirically supported therapeutic compounds
In 2017, Dr. Adi Aran conducted the world’s most comprehensive study on the effects of CBD oil on children with autism. It was also the first double-blind placebo-controlled trial of its kind. The results of the study were encouraging, with 49% of one group reporting an improvement in disruptive behavior. But it was also clear that there was a need for follow up research.
In 2019, a second study focused on children diagnosed with ASD, which was also characterized by severe behavior disturbance. The results of this study also showed a positive correlation between CBD and reduced symptoms:
In addition to CBD, proprietary compounds have demonstrated particular efficacy for treating ASD associated symptoms in preliminary trials.
Each of these compounds on their own demonstrated limited efficacy, which is attributed to the highly complex nature of ASD. A combined treatment with these compounds can lead to a significantly greater reduction of disruptive behavior and core autistic symptoms while limiting side effects
GCANRx has teamed up with a world renowned research center to treat 100 children diagnosed with ASD and related behavioral problems, with a combination of CBD, and additional proprietary compounds for up to 24 weeks.
combining proven CBD with empirically supported therapeutic compounds
as well as anecdotal and predecessor clinical results
in the field with a proven track record of results
ensures the uniqueness of the study and patentability of its results
© 2023 The Greater Cannabis Company, Inc. ALL Rights Reserved